Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy
NCT ID: NCT04161053
Last Updated: 2019-11-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
60 participants
INTERVENTIONAL
2018-11-01
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis
NCT02120196
Nitazoxanide in Prevention of Secondary Spontaneous Peritonitis
NCT04746937
Oral Gemifloxacin Versus Intravenous Cefotaxime in Treatment of Spontaneous Bacterial Peritonitis
NCT04168099
Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy
NCT03077217
Rifaximin Predicts the Complications of Decompensated Cirrhosis
NCT02074280
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Rifaximin
550 mg Rifaximin tablets twice daily for six months.
Rifaximin
Rifaximin 550 mg twice daily for 6 months
Nitazoxanide
500 mg Nitazoxanide tablets twice daily for six months.
Nitazoxanide
Nitazoxanide 500 mg twice daily for 6 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rifaximin
Rifaximin 550 mg twice daily for 6 months
Nitazoxanide
Nitazoxanide 500 mg twice daily for 6 months
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adult Patients aging from 20 to 65 years old
Exclusion Criteria
* Major psychiatric illness (psychosis \& epilepsy).
* Renal insufficiency (S.Cr 2mg/dl).
20 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sherief Abd-Elsalam
Ass. Prof. Tropical Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Khadija Ahmed Glal, Msc
Role: PRINCIPAL_INVESTIGATOR
Tanta University
Tarek Mohamed Mostafa, ass, Prof.
Role: PRINCIPAL_INVESTIGATOR
Tanta University
Sherief Abd-Elsalam, Ass. Prof.
Role: PRINCIPAL_INVESTIGATOR
Tanta University - Tropical Medicine Department
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sherief Abd-Elsalam
Tanta, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Sherief Abd-Elsalam
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Encephalopathy
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.